Back to top
more

Interpace Biosciences (IDXG)

(Delayed Data from OTC)

$1.50 USD

1.50
5,677

+0.08 (5.45%)

Updated Apr 26, 2024 03:52 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 252)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

TherapeuticsMD (TXMD) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -53.43% and 30.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Organon (OGN) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Organon (OGN) delivered earnings and revenue surprises of 17.86% and 2.94%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

UpHealth, Inc. (UPH) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

UpHealth, Inc. (UPH) delivered earnings and revenue surprises of -28.57% and 2.86%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

CareDx (CDNA) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

CareDx (CDNA) delivered earnings and revenue surprises of -62.50% and 3.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

XpresSpa Group, Inc. (XSPA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

XpresSpa Group, Inc. (XSPA) delivered earnings and revenue surprises of 33.33% and 23.83%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Organon (OGN) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Organon (OGN) delivered earnings and revenue surprises of 25.95% and 3.88%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Assure Holdings Corp. (IONM) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Assure Holdings Corp. (IONM) delivered earnings and revenue surprises of -50% and 8.53%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

LifeMD, Inc. (LFMD) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

LifeMD, Inc. (LFMD) delivered earnings and revenue surprises of 25.64% and 0.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Interpace Biosciences, Inc. (IDXG) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Interpace Biosciences, Inc. (IDXG) delivered earnings and revenue surprises of -72.92% and 0.50%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Interpace Biosciences, Inc. (IDXG) Is a Great Choice for "Trend" Investors, Here's Why

by Zacks Equity Research

Interpace Biosciences, Inc. (IDXG) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Will Interpace Diagnostics (IDXG) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Interpace Diagnostics (IDXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sweta Killa headshot

Best ETFs & Stocks From the Top Sector of Q3

by Sweta Killa

Healthcare was the best-performing sector of the third quarter, jumping 14.1% - its highest quarterly gain since the first quarter of 2013.

    LabCorp Forms Lab-Alliance With Kentucky-Based Health Firm

    by Zacks Equity Research

    The multi-year, comprehensive laboratory deal to help LabCorp (LH) provide high-quality, high-value and standardized laboratory diagnostics for Appalachian Regional Healthcare.

      LabCorp & Interpace Team Up, Drive Specialty Diagnostics

      by Zacks Equity Research

      Per the new deal with Interpace, Dianon Pathology, member of the LabCorp (LH) Specialty Testing Group, is supposed to perform the thyroid biopsy analysis.

        LabCorp Completes $1.2-Billion Chiltern Buyout, Boosts CRO

        by Zacks Equity Research

        In line with its inorganic growth strategy, LabCorp's (LH) latest Chiltern buyout is aimed at promoting the CRO business.

          6 Things to Know About Business Services Sector

          by Zacks Equity Research

          Stocks in the Business Services sector have been strong performers lately, with the sector in the S&P 500 up more than the index both in the year-to-date and trailing 12-month periods.